Autoantibodies against Cardiolipin in the Serum of Patients with Colorectal Adenocarcinoma:Their Prognostic Significance

Syrigos, Kostas; Charalampopoulos, Athanasios; Konstantoulakis, Manousos; Karayiannakis, Anastasios J.; Tsibloulis, V.; Peveretos, P

doi:10.1159/000008558

Cited by 8 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 235 patients with GI cancer were evaluated in 5 studies; patients were 5.1 times more likely than controls to develop aCL antibodies (95% CI, 2.6-9.95) (Table 1). [26][27][28][29][30] Two studies included patients with GU cancer (n 5 49) with increased pooled risk of developing aCL antibodies compared with healthy controls (RR, 7.3; 95% CI, 3.3-16.2). 30,31 Pooled risk estimates from 2 studies evaluating 62 patients with breast cancer were not statistically significant (RR, 1.9; 95% CI, 0.19-19.9).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…For this analysis, we included the prevalence of antibodies for all studies, with or without controls (Table 2). The pooled prevalence rates of the various types of cancer ranged between 7% and 28% for aCL antibodies, 19,[24][25][26][27][28][29][30][31][32][40][41][42][43][44][45][46][47][48][49][50] between 5% and 53% for anti-b2-GPI antibodies, [24][25][26]33,40,42,44,45,51,52 and from 3% to 80% for LA. [23][24][25]32,45,49,50,53,54 Two studies examined all 3 aPL antibodies, but none of them reported the percentage of patients who were positive for all 3; therefore, the pooled prevalence rate of triplepositive aPL antibodies could not be determined.…”

Section: Pooled Prevalence Rates Of Developing Apl Antibodies In Patients With Solid Tumors (31 Studies)mentioning

confidence: 99%

See 1 more Smart Citation

Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors

et al. 2020

View full text Add to dashboard Cite

This review summarizes the evidence on antiphospholipid (aPL) antibodies and related thromboembolic events in patients with solid tumors. Data sources included Medline, EMBASE, Web of Science, PubMed ePubs, and the Cochrane Central Register of Controlled Trials through August 2019 without restrictions. Observational studies that evaluated patients with solid tumors for the presence of aPL antibodies were included. Data were extracted and quality was assessed by one reviewer and cross-checked by another. Thirty-three studies were identified. Gastrointestinal (GI) and genitourinary (GU) cancers were the most frequently reported. Compared with healthy patients, patients with GI cancer were more likely to develop anticardiolipin antibodies (risk ratio [RR], 5.1; 95% confidence interval [CI], 2.6-9.95), as were those with GU (RR, 7.3; 95% CI, 3.3-16.2) and lung cancer (RR, 5.2; 95% CI, 1.3-20.6). The increased risk for anti-β2-glycoprotein I or lupus anticoagulant was not statistically significant. Patients with lung cancer who had positive aPL antibodies had higher risk of developing thromboembolic events than those who had negative antibodies (RR, 3.8%; 95% CI, 1.2-12.2), while the increased risk in patients with GU cancer was not statistically significant. Deaths due to thromboembolic events were more common among patients with lung cancer who had elevated aPL antibodies. A limitation of this review is that the results are contingent on the reported information. We found an increased risk of developing aPL antibodies in patients with GI, GU, and lung cancers resulting in thromboembolic events and death. Further studies are needed to better understand the pathogenesis and development of aPL antibodies in cancer.

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

Section: Pooled Prevalence Rates Of Developing Apl Antibodies In Patients With Solid Tumors (31 Studies)mentioning

confidence: 99%

Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors

et al. 2020

View full text Add to dashboard Cite

show abstract

“…We also collected multiple autoantibodies in 42 different combinations for CRC (Table 2). 11-83 The research was mainly undertaken in China (n = 20) and the USA (n = 12), with the remainder in Japan, Germany, Spain, and elsewher...…”

Section: Resultsmentioning

confidence: 99%

Autoantibodies as biomarkers for colorectal cancer: A systematic review, meta-analysis, and bioinformatics analysis

Wang

Zhou

et al. 2019

Int J Biol Markers

View full text Add to dashboard Cite

Colorectal cancer is a very common cancer worldwide. Serum tumor-associated autoantibodies (TAAbs), especially the anti-p53 autoantibody, may be promising biomarkers to detect early-stage colorectal cancer. This study aimed to identify all known autoantibodies and their value in colorectal cancer diagnosis, as well as exploring the underlying connections and mechanisms through a bioinformatics analysis. Databases were used to select available articles of TAAbs in colorectal cancer. In a meta-analysis of the anti-p53 autoantibody, the diagnostic odds ratio and area under the curve (AUC) of the summary receiver-operating characteristic (SROC) curve were calculated using Stata 12.0 and Meta-Disc 1.4. We identified 73 articles including 199 single autoantibodies and 42 multiple autoantibodies. The maximum value of Youden's index was 0.76, combining c-MYC, p53, cyclin B1, p62, Koc, IMP1, and survivin. The diagnostic odds ratio for anti-p53 autoantibody at all stages was 10.86 (95% CI 8.40, 14.06) with low heterogeneity (I 2 = 40.3%) and the AUC of the SROC curve was 0.82. For the anti-p53 autoantibody in early-stage colorectal cancer, the diagnostic odds ratio was 4.82 (95% CI 2.95, 7.87) with heterogeneity (I 2 = 7.9%) and the AUC of the SROC curve was 0.72. Eighty-seven autoantibodies were selected for bioinformatics analyses. We found that the most enriched functional terms and protein-protein interactions may relate to the mechanism of autoantibody generation. In summary, our study summarized the diagnostic value of TAAbs in colorectal cancer, either as single molecules or in combination. Bioinformatics analyses may be a new approach to explore the mechanism of autoantibody generation.

show abstract

“…In addition, the reference lists of review articles and related articles were manually screened to identify additional studies. Finally, a total of 80 articles involving 145 specific tumour‐associated autoantibodies detected in patients with CRC were selected (Table ) . Anti‐p53 antibody was the most commonly studied autoantibody, followed by MUC1, CEA, c‐myc, survivin, HDAC5, p62, ANXA4, koc, NY‐CO‐16, NY‐ESO‐1, RPH3AL, cyclin B, Imp1, IMPDH2 and MAGEA3.…”

Section: Resultsmentioning

confidence: 99%

Anti‐p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: A meta‐analysis

et al. 2019

View full text Add to dashboard Cite

Serum autoantibodies against tumour-associated antigens are promising biomarkers for diagnosis of cancer. This review summarizes the available evidence pertaining to the diagnostic potential of autoantibodies studied in the context of colorectal cancer (CRC). A systematic literature search was conducted in three databases (PubMed, Cochrane Library and Embase). Data pertaining to a total of 145 autoantibodies published in 80 articles were reviewed. Of these, anti-p53 antibody was the most commonly studied autoantibody; thus, we performed a meta-analysis on anti-p53 antibody in 24 articles. According to the cut-off values used to determine positivity for anti-p53 antibody, we divided the included studies into five groups. Owing to the presence of threshold effect in groups 4 and 5 and non-threshold effect in groups 1 and 2, pooled analysis focused on group 3 using a fixed-effects model (Mantel-Haenszel). Group 3, determining the cut-off value based on the value of p53 antibody titre index, was comprised of five articles including 733 patients with CRC and 172 controls (126 healthy individuals and 46 benign diseases). The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and summary area under the receiver operating characteristic curves were 0. 21, 0.99, 12.26, 0.80, 15.46 and 0.87, respectively. Serum anti-p53 autoantibody may potentially help distinguish CRC from healthy controls or benign diseases; however, it should be used in combination with other indicators due to the low sensitivity. Our study provides insights for further exploration of the optimal combination of different tumour-associated antigens or autoantibodies for diagnosis of CRC.

show abstract

Autoantibodies against Cardiolipin in the Serum of Patients with Colorectal Adenocarcinoma:Their Prognostic Significance

Cited by 8 publications

References 18 publications

Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors

Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors

Autoantibodies as biomarkers for colorectal cancer: A systematic review, meta-analysis, and bioinformatics analysis

Anti‐p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: A meta‐analysis

Contact Info

Product

Resources

About